News

The COMET-1 trial evaluated cabozantinib in mCRPC patients whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial failed to meet its primary

NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone

APD811 is an investigational drug candidate internally discovered and developed by Arena for the treatment of vasospastic diseases, such as PAH. Arena Operations Global Regulatory Affairs senior vice-president

Motolimod is indicated for ovarian cancer patients whose disease has progressed on or recurred after platinum-based chemotherapy. The new Toll-like receptor 8 (TLR8) immunotherapy, motolimid is currently being

The data will be presented during the European Society of Cardiology congress1 taking place between 30 August and 3 September 2014 in Barcelona. ATLANTIC was designed to evaluate

The TaNeDS program was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded abroad, opening up to researchers

Bile acids are essential for regulating cholesterol metabolism and the intestinal digestion and absorption of fat. Their signaling functions play an important role in chronic disorders, sepsis, or

Boehringer Ingelheim continues to grow the evidence base for Pradaxa to improve care for patients at risk of blood clots and today announces the initiation of Phase III

The active substance in Somatuline is lanreotide acetate, a somatostatin analogue that inhibits the secretion of several endocrine, exocrine and paracrine amines and peptides. Decision from the FDA